Introduction
Three groups in a bank can work for the same private equity firm in the same month without doing the same kind of job. Financial sponsors coverage, usually called the financial sponsors group (FSG), is a coverage group: it owns the bank's relationship with private equity firms and brings the bank's products to them. M&A is a product group that executes the purchase and sale of companies for corporate and sponsor clients alike. Private capital advisory is a specialist product team whose transactions happen one layer up, at the fund, the manager, and the limited partner.
Banks staff the three differently, but the transactions underneath them differ in consistent, testable ways.
A Coverage Group, a Product Group, and a Fund-Level Specialist
The coverage-versus-product split, set out in this overview of how banks divide coverage and product groups, comes first. A coverage banker is judged on the relationship and on wallet share, the portion of a client's fee spend the bank captures across products; a product banker is judged on executing one type of transaction.
- Coverage Group vs Product Group
A coverage group owns client relationships, organized by industry or, for financial sponsors, by client type, and brings in specialists when a client needs a transaction. A product group owns execution expertise in one kind of transaction, such as M&A, leveraged finance, or private capital advisory, and works with clients across coverage teams.
FSG sits on the coverage side: its client is the sponsor as a firm, and on a given deal it may lead execution, share it with M&A or leveraged finance, or mainly coordinate, as the financial sponsors group explainer describes. PCA sits on the product side with a twist: because pensions, endowments, and secondary funds are not accounts a sponsors team manages, PCA builds and keeps its own relationships with the LP and secondary buyer community, the institutions described in the overview of what PCA bankers do.
Five Dimensions Where PCA, Sponsors Coverage, and M&A Differ
Five dimensions separate the three groups more reliably than any label: the client layer, the asset, the counterparty, the pricing language, and the fee model.
| Dimension | Private capital advisory | Financial sponsors coverage | M&A |
|---|---|---|---|
| Client and layer | GPs, their funds, and LPs, at the fund and manager level | The sponsor as a firm, across its whole portfolio | A company, its corporate parent, or a sponsor as owner or buyer |
| What changes hands | Fund interests, CV assets, fund commitments, manager stakes, fund financing | Whatever the sponsor needs, via product teams | Companies, divisions, and stakes in them |
| Across the table | Secondary funds, evergreen vehicles, LPs, GP stakes buyers, fund lenders | Rival banks for the sponsor's wallet, plus each deal's counterparties | Strategic acquirers and financial sponsors |
| Pricing language | Percentage of NAV at a reference date, capital raised, manager earnings | Ability to pay, leverage, IRR and MOIC | Enterprise value, multiples, DCF, synergies |
| How the bank is paid | Success fees on secondaries, placement fees on capital raised, advisory fees | Fees booked by the product teams, with credit shared | Advisory fees, largely contingent on closing |
What Is Sold and Who Sits Across the Table
An M&A sale markets a company to strategic acquirers, who can pay for synergies, and to financial sponsors, whose price is capped by the return the deal can generate, which is why bankers treat an LBO as the measure of what financial buyers can afford. This comparison of secondary buyouts and strategic exits shows the trade-off from the seller's side. PCA sells things no strategic would buy. A fund interest is a partnership position with exposure to many companies, cash flows the GP controls, and often unfunded commitments the buyer must honor; a CV stake is exposure to one or a few companies alongside a GP that keeps control.
The buyers are financial investors pricing to a target return: secondary funds such as Ardian, Lexington, and HarbourVest, evergreen vehicles, and other LPs. There is no synergy premium to chase, and the buyer universe is small enough that the same investors see process after process, so knowing each buyer's appetite is a core advisory asset. The seller also has less control than in M&A: an LP selling a fund interest usually needs the GP's consent to the transfer, which gives each underlying GP leverage over timing.
How Mandates Arise and How They Are Paid
M&A mandates are event-driven: a board decides to sell or a sponsor reaches its exit window, and the fee is largely contingent on closing. Sponsors coverage is continuous, and its fee event is whichever product the sponsor buys. PCA mandates follow the fund lifecycle rather than a single company event: a fundraise, a liquidity review as a fund ages, or an LP's rebalancing each produces a different mandate, paid as success fees on secondaries, placement fees on capital raised, or advisory fees on GP stakes and structured work.
How PCA firms make money covers the detail, but one feature has no M&A equivalent. For GP-led deals, the Institutional Limited Partners Association (ILPA) recommends in its 2023 continuation fund guidance that the LPAC review the advisor's fee arrangement and that transaction costs be allocated among the acquirer, selling LPs, rolling LPs, and the GP according to who benefits, with the method disclosed. These are recommendations, not law, but they shape how GP-led fees are negotiated.
The Analytical Toolkit: Enterprise Value Versus NAV
Each group asks a different valuation question:
- M&A: what will the best buyer pay for this company, judged through comps, precedents, a DCF, and any synergies a strategic can underwrite?
- Sponsors coverage: what can this sponsor afford to pay, finance, and later exit at its target return?
- PCA: what is this fund position worth relative to the GP's last mark, given the capital still to be called, the cash expected back and when, and the buyer's return target?
The PCA question starts from net asset value at a reference date, a figure the GP sets rather than the market, which is why how NAV is set underpins this guide. The work is fund-level: projecting contributions and distributions, testing marks, and expressing bids as a discount to NAV. Company valuation still matters on single-asset deals, but it feeds the fund-level price rather than replacing it.
Where the Three Desks Meet: The Continuation Vehicle
A sponsor holding a strong asset in an ageing fund has several routes to liquidity: a strategic sale, a secondary buyout, an IPO, a dividend recap, or a continuation vehicle. FSG typically pitches the first four alongside the M&A, capital markets, and leveraged finance teams that execute them; the CV is a PCA product. ILPA's 2023 guidance recommends that a GP present its rationale to the LPAC and show it explored alternative options for the asset, so a well-run CV is compared against a sale by design, the comparison worked through in CV vs sale vs dividend recap.
The 2020 attempt was an M&A process aimed at buyers of a company; both CVs, including the one described in Curium's November 2025 recapitalization announcement, were fund-level transactions, priced among secondary investors and offered to existing LPs as a choice to sell or roll, with the same sponsor in control throughout.
Single-Asset CVs: The PCA Deal That Looks Like M&A
A single-asset CV has many surface features of a company sale. The lead investor diligences one business and meets management, and the advisor's models and data room resemble a sell-side process, which is why CV teams prize M&A-style company analysis.
- Single-Asset Continuation Vehicle
A continuation vehicle that buys one portfolio company from an existing fund managed by the same GP, giving existing LPs the choice to sell or roll and bringing in new secondary investors while the GP keeps control. Because all the risk sits in one business, buyers diligence it much as they would a direct acquisition.
What still makes it a PCA transaction is structural, and it is what an interviewer is testing when the question comes up.
Where the Comparison Breaks Down
The table treats PCA as one business, but its lines each resemble a different part of the bank. An LP portfolio sale is an auction of many small positions rather than one company. Primary placement is a distribution business, closer to a securities offering than to M&A. The comparison with FSG and M&A holds best for secondaries and weakest for placement and fund finance.
The contrast that carries across all of them is the pricing reference: FSG covers the sponsor as a buyer and seller of companies, M&A executes those deals against strategic and sponsor buyers valued on enterprise value, and PCA transacts in fund interests, commitments, and manager stakes priced off NAV. Which seat suits a particular candidate is a separate decision, covered in the careers comparison of PCA, sponsors, and M&A seats. Curium shows the shift in one company: when it moved from an M&A process to fund-level transactions, the counterparties, the pricing language, and the desk all changed with it.
